Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 70.63B |
| Revenue (ttm) | 56.02B |
| Net Income (ttm) | -528.98M |
| Shares Out | n/a |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | 7.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 391,443 |
| Average Volume | 2,891,704 |
| Open | 6,140.00 |
| Previous Close | 6,002.00 |
| Day's Range | 6,122.00 - 6,153.00 |
| 52-Week Range | 4,865.00 - 8,431.00 |
| Beta | 0.62 |
| RSI | 54.91 |
| Earnings Date | Nov 5, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major pl...
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
The FDA signed off on the first-ever weight-loss generic on Thursday, a knockoff of Novo Nordisk's Saxenda from Teva Pharmaceutical.
Teva gets FDA nod for generic version of Novo's weight loss drug
US FDA approves Teva Pharmaceuticals' generic obesity drug
The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.
Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue
Teva Pharmaceutical: Tariff Relief Clears The Way For Reinvention
Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”
GOLETA, Calif.--(BUSINESS WIRE)--Teva unveils AW25 footwear collection.
How Is The Market Feeling About Teva Pharmaceutical Indus?
Teva Pharmaceutical Indus's (NYSE: TEVA) short percent of float has fallen 6.62% since its last report. The company recently reported that it has 49.89 million shares sold short , which is 4.37% of a...
Teva Pharmaceutical continues gains for seven straight sessions
Teva wins FDA label expansion for migraine therapy Ajovy in children and adolescents
Teva (TEVA) stock in focus as the FDA expands label for its migraine therapy Ajovy for children and adolescents aged 6–17 years. Read more here.
US FDA approves Teva's Ajovy for migraine prevention in children
The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help prevent migraines in children aged six and older who weigh 45 kilograms or...
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva CEO: Our supply chain puts us in a strong position
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Teva CEO: Our supply chain puts us in a strong position
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Teva raises 2025 EPS outlook and innovative product guidance as company targets $700M in cost savings by 2027
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript
Teva posts Q2 revenue miss as generic products underperform
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
Teva stock is trading below key levels.
Teva Pharm Q2 profit beats estimates as branded drugs gain
Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophren...
Teva Pharmaceutical Non-GAAP EPS of $0.66 beats by $0.04, revenue of $4.18B misses by $90M
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its second-quarter 2025 financial results tomorrow, July 30 . According to Benzinga Pro , the company expects to report second-quarter ea...
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
Teva Pharmaceutical Industries Ltd. TEVA will release its second-quarter 2025 financial results tomorrow, July 30.
A Glimpse of Teva Pharmaceutical Indus's Earnings Potential
Teva Pharmaceutical Indus (NYSE: TEVA) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement. Analysts estimate that...
Teva Pharmaceutical Q2 2025 Earnings Preview
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc . (NASDAQ: VTRS) on Friday announced topline data from a Phase 3 study evaluati...